Related Experiment Video
Updated: May 31, 2026

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines
Cheng-Cheng Xu1, Lei-Ming Wu, Wei Sun
1Department of General Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China.
Abstract:
Transforming growth factor β (TGF-β) is overexpressed in a wide variety of cancer types including lung adenocarcinoma (LAC), and the TGF-β signaling pathway plays an important role in tumor development. To determine whether blockade of the TGF-β signaling pathway can inhibit the malignant biological behavior of LAC, RNA interference (RNAi) technology was used to silence the expression of TGF-β receptor, type II (TGFβRII) in the LAC cell line, A549, and its effects on cell proliferation, invasion and metastasis were examined. Three specific small interfering RNAs (siRNAs) designed for targeting human TGFβRII were transfected into A549 cells. The expression of TGFβRII was detected by Western blot analysis. Cell proliferation was measured by MTT and clonogenic assays. Cell apoptosis was assessed by flow cytometry. The invasion and metastasis of A549 cells were investigated using the wound healing and Matrigel invasion assays. The expression of PI3K, phosphorylated Smad2, Smad4, Akt, Erk1/2, P38 and MMPs was detected by Western blot analysis. The TGFβRII siRNA significantly reduced the expression of TGFβRII in A549 cells. The knockdown of TGFβRII in A549 cells resulted in the suppression of cell proliferation, invasion and metastasis and induced cell apoptosis. In addition to the Smad-dependent pathway, independent pathways including the Erk MAPK, PI3K/Akt and p38 MAPK pathways, as well as the expression of MMPs and VEGF, were inhibited. In conclusion, TGF-β signaling is required for LAC progression. Therefore, the blockade of this signaling pathway by the down-regulation of TGFβRII using SiRNA may provide a potential gene therapy for LAC.
Insights
Blocking TGF-β receptor type II (TGFβRII) with RNA interference in lung adenocarcinoma (LAC) cells suppressed tumor growth, invasion, and metastasis. This suggests targeting TGFβRII offers a potential gene therapy for LAC progression.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Transforming growth factor β (TGF-β) is overexpressed in lung adenocarcinoma (LAC), promoting tumor development.
- The TGF-β signaling pathway is crucial for the progression of various cancers, including LAC.
Purpose of the Study:
- To investigate if blocking the TGF-β signaling pathway can inhibit malignant behaviors in LAC.
- To evaluate the effects of silencing TGF-β receptor type II (TGFβRII) expression on LAC cell proliferation, invasion, metastasis, and apoptosis.
Main Methods:
- Utilized RNA interference (RNAi) with small interfering RNAs (siRNAs) to silence TGFβRII expression in the A549 LAC cell line.
- Assessed TGFβRII expression via Western blot; measured cell proliferation (MTT, clonogenic assays), apoptosis (flow cytometry), invasion, and metastasis (wound healing, Matrigel assays).
- Analyzed downstream signaling pathways (Smad, Erk MAPK, PI3K/Akt, p38 MAPK) and expression of MMPs and VEGF.
Main Results:
- TGFβRII siRNA significantly reduced TGFβRII expression in A549 cells.
- Knockdown of TGFβRII suppressed cell proliferation, invasion, and metastasis while inducing apoptosis.
- Inhibition of TGFβRII affected both Smad-dependent and independent pathways, including Erk MAPK, PI3K/Akt, p38 MAPK, MMPs, and VEGF.
Conclusions:
- TGF-β signaling is essential for LAC progression.
- Down-regulating TGFβRII via siRNA effectively inhibits LAC cell malignant behaviors.
- Targeting TGFβRII represents a potential gene therapy strategy for lung adenocarcinoma.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019